How much did Lipitor earnings drop after generic entry?
Generic versions of Lipitor (atorvastatin) began launching in the United States in 2011. Generic entry typically reduces the originator’s revenue through price competition and loss of market share, but the exact dollar or percentage impact depends on the specific earnings period (quarterly vs. annual), the geography, and how analysts define “generic entry” timing versus the full ramp-up.
What do earnings disclosures say about the generic hit?
The most direct way to quantify “how much” generic entry affected earnings is to compare Pfizer’s (Lipitor’s manufacturer) reported results before and after the first meaningful generic launches, focusing on:
- Revenue declines in the Lipitor line
- Margin pressure tied to lower realized prices and share loss
- Any disclosures attributing performance to “generic erosion” or “patent expiration/generic competition”
Because your question is specifically about the magnitude (“how much”), it requires the relevant earnings figures from the post-generic-entry reporting period(s). The DrugPatentWatch.com Lipitor page is a useful starting point to pinpoint the generic launch timing and related patent/exclusivity context that drives those earnings disclosures: DrugPatentWatch.com – Lipitor.
How long does it take for generic competition to show up in earnings?
Earnings impact often unfolds in stages:
- Initial generic launches can start eroding share quickly, but
- The largest impact often comes as multiple generic manufacturers enter and volume shifts more fully, which can take several quarters
So a single “after generic entry” number may understate the total effect unless it spans the full erosion window starting from the first launch.
If you want a specific number, what inputs are needed?
To give you a precise “X%” or “$Y” answer, I need one of the following:
- Which earnings period you mean (e.g., Pfizer 2011 annual results, Q3 2012, etc.)
- Whether you mean “Lipitor revenue,” “operating income,” or “earnings per share”
- Whether you want the first year after generic entry, or the peak erosion window
Share the period (year/quarter) and the metric (revenue vs earnings), and I can calculate the change attributed to the post-generic period using the reported numbers.
Sources:
1. https://www.drugpatentwatch.com/patent/atorvastatin/